| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 02/19/2004 | WO2004014940A2 PEPTIDES AS SOLUBILIZING EXCIPIENTS FOR TRANSFORMING GROWTH FACTOR ß PROTEINS |
| 02/19/2004 | WO2004014938A2 Thrombopoiesis-stimulating proteins having reduced immunogenicity |
| 02/19/2004 | WO2004014936A2 Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof |
| 02/19/2004 | WO2004014433A1 Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit |
| 02/19/2004 | WO2004014424A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 02/19/2004 | WO2004014420A1 Pharmaceutical compositions comprising an hiv envelope protein and cd4 |
| 02/19/2004 | WO2004014419A1 Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria |
| 02/19/2004 | WO2004014418A2 Neisserial vaccine compositions comprising a combination of antigens |
| 02/19/2004 | WO2004014417A2 Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis |
| 02/19/2004 | WO2004014415A1 Growth hormone releasing peptides |
| 02/19/2004 | WO2004014414A1 Novel uses of rfrp and ot7t022 |
| 02/19/2004 | WO2004014359A1 Regulation of apob in treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
| 02/19/2004 | WO2004014311A2 Nogo receptor antagonists |
| 02/19/2004 | WO2004014299A2 Antisense modulation of resistin expression |
| 02/19/2004 | WO2004007726A3 Brachyspira hyodysenteriae vaccine |
| 02/19/2004 | WO2004007539A3 Hsp70 from arthrobacter |
| 02/19/2004 | WO2004003133A8 Pain signaling molecules |
| 02/19/2004 | WO2003106490B1 A fusion protein comprising a cellulose binding domain |
| 02/19/2004 | WO2003103719A3 Method for triggering apoptosis in cells by increasing the level of c1d and inhibiting the degradation of the same |
| 02/19/2004 | WO2003102584A3 Semaphorin-like proteins and methods of using same |
| 02/19/2004 | WO2003102137A3 Compositions and methods relating to lung specific genes and proteins |
| 02/19/2004 | WO2003102129A3 Photorhabdus luminescens mcf toxin genes and uses thereof |
| 02/19/2004 | WO2003100060A3 Muc-1 antigen with reduced number of vntr repeat units |
| 02/19/2004 | WO2003099863A3 Resistin binding proteins, their preparation and use |
| 02/19/2004 | WO2003099193A3 Vaccines |
| 02/19/2004 | WO2003097834A3 A method for in vitro molecular evolution of protein function |
| 02/19/2004 | WO2003095605A3 A chimeric reverse transcriptase and methods for identifying telomerase inhibitors |
| 02/19/2004 | WO2003088979A3 Oligonucleotides from sequences coding for the surface component of envelope proteins of primate t-cell leukaemia/lymphoma viruses (ptlv) and uses thereof |
| 02/19/2004 | WO2003087318A3 Truncated 24 kda basic fibroblast growth factor |
| 02/19/2004 | WO2003085124A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/19/2004 | WO2003084986A3 Novel purified polypeptides involved in cellular metabolism |
| 02/19/2004 | WO2003080640B1 Lymphatic and blood endothelial cell genes |
| 02/19/2004 | WO2003079968A3 Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ |
| 02/19/2004 | WO2003078584A3 Identifying peptide modifications |
| 02/19/2004 | WO2003077835A3 Sodium dodecyl sulfate compositions for inactivating prions |
| 02/19/2004 | WO2003076595A3 Production of insulin and insulin-like proteins in plants |
| 02/19/2004 | WO2003075790A3 Gas-plasma treatment of implants |
| 02/19/2004 | WO2003072803A3 Nanostructures containing antibody assembly units |
| 02/19/2004 | WO2003069347A3 Diagnostic and therapeutic use of caps |
| 02/19/2004 | WO2003066652A8 Jlp cytoplasmic scaffolding protein and nucleic acids encoding it |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003065045A3 Diagnostics and therapeutics for diseases associated with the gpr65 receptor |
| 02/19/2004 | WO2003065010A3 Identification of epitopes on staphylococcal enterotoxins that inhibit transcytosis |
| 02/19/2004 | WO2003064602A3 Methods of modulating cold sensory perception |
| 02/19/2004 | WO2003054172A3 Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium |
| 02/19/2004 | WO2003053136A3 Triple transgenic mouse model of alzheimer's disease |
| 02/19/2004 | WO2003052051A3 Adeno-associated virus (aav) serotype 8 sequences |
| 02/19/2004 | WO2003051913A3 Antigens for actinobacillus pleuropneumoniae and methods thereof |
| 02/19/2004 | WO2003050265A3 Compositions and methods for normalizing assays |
| 02/19/2004 | WO2003049683A3 Use of parapox b2l protein to treat cancer and modify immune responses |
| 02/19/2004 | WO2003048297A3 Regulation of human atp-binding cassette transporter 1 like-protein |
| 02/19/2004 | WO2003048193A3 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN |
| 02/19/2004 | WO2003046571A3 Hp and apolipoprotein biopolymer markers predictive of alzheimers disease |
| 02/19/2004 | WO2003046149A3 Methods of using improved polymerases |
| 02/19/2004 | WO2003042364A3 Identifying and controlling the growth of estrogen-responsive cells |
| 02/19/2004 | WO2003040306A3 Compositions from the grasses lolium perenne and festuca arundinacea |
| 02/19/2004 | WO2003038724A3 Methods and apparatus for protein sequence analysis |
| 02/19/2004 | WO2003034072A3 Diagnosis and therapy of conditions involving alms1 |
| 02/19/2004 | WO2003033520A3 Anticancer vaccine and diganostic methods and reagents |
| 02/19/2004 | WO2003029454A3 Non-human animal model for analysis of the origin and therapy of organ fibrosis |
| 02/19/2004 | WO2003027291A3 Hdv nucleic acid molecules, fragments and applications thereof |
| 02/19/2004 | WO2003027139A3 Novel purified polypeptides involved in membrane biosynthesis |
| 02/19/2004 | WO2003025014A3 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 02/19/2004 | WO2003020212A3 Treatment for central nervous system disorders |
| 02/19/2004 | WO2003018770A3 Amplified oncogenes and their involvement in cancer |
| 02/19/2004 | WO2003018621A8 Genes |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2003010291A3 Treatment of immune disorders and b cell disorders |
| 02/19/2004 | WO2003008537A9 Epitope sequences |
| 02/19/2004 | WO2003004622A3 Human secreted proteins |
| 02/19/2004 | WO2003004532A3 Q9ul33/q9nzz4 and q9h5p3 splice variants |
| 02/19/2004 | WO2003000719A8 Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same |
| 02/19/2004 | WO2002099085A3 Human secreted proteins |
| 02/19/2004 | WO2002097072A8 Influenza vaccine composition |
| 02/19/2004 | WO2002092835A3 Isolated human g protein-coupled receptor |
| 02/19/2004 | WO2002091991A3 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use |
| 02/19/2004 | WO2002088184A9 A molecular marker |
| 02/19/2004 | WO2002086101A3 Core-glycosylated hcv envelope proteins |
| 02/19/2004 | WO2002086100A3 Expression of core-glycosylated hcv envelope proteins in yeast |
| 02/19/2004 | WO2002083876A3 Secretory molecules |
| 02/19/2004 | WO2002083866A3 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| 02/19/2004 | WO2002081622A3 Plants characterized by enhanced growth and methods and nucleic acid constructs useful for generating same |
| 02/19/2004 | WO2002079231B1 Nucleic acids encoding isav polypeptides |
| 02/19/2004 | WO2002078613A3 Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response |
| 02/19/2004 | WO2002077190A3 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof |
| 02/19/2004 | WO2002076380A3 Cytotoxic factors for modulating cell death |
| 02/19/2004 | WO2002072614A8 Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins |
| 02/19/2004 | WO2002069884A3 A sunburn treatment and sunburn prevention method |
| 02/19/2004 | WO2002068596A3 Mammalian cytokines; related reagents |
| 02/19/2004 | WO2002066498A3 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 02/19/2004 | WO2002065985A3 Methods of treating diabetes mellitus |
| 02/19/2004 | WO2002061086A3 Human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1 |
| 02/19/2004 | WO2002059248A3 A novel gene associated with regulation of adiposity and insulin response |
| 02/19/2004 | WO2002048346A3 Transgenic mice containing bsmap gene disruptions |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002048184A8 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test |
| 02/19/2004 | WO2002046477A3 Endogenous retroviruses up-regulated in prostate cancer |
| 02/19/2004 | WO2002042328A3 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| 02/19/2004 | WO2002038595A3 Crystals and structure of luxs |
| 02/19/2004 | WO2002028888A3 Mimotope of neisseria meningitides lipooligosaccharide and vaccines containing the same |